NEW YORK (GenomeWeb) – Dako, an Agilent subsidiary, has declared CE Mark self-certification for its PD-L1 IHC 22C3 pharmDx, a companion diagnostic to identify best responders to Merck's anti-PD-1 immunotherapy Keytruda (pembrolizumab).

Dako developed the PD-L1 IHC 22C3 pharmDx test in partnership with Merck. By affixing a CE Marking on a product, the manufacturer is declaring that it is in conformity with EU legislation and requirements and can now be sold throughout the European Economic Area.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec
04
Sponsored by
Sophia Genetics

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Dec
12

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.